Search Results
Your search for AT matches 28875 pages
Showing 2301 - 2350Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer
A rare subset of T cells called V-delta 1 gamma-delta (Vd1-gd) T cells could help predict which patients with advanced skin cancer may be responsive to immunotherapy, according to a novel study published by Davies et al in Nature Cancer. The new findings may lead to the development of new and more...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
Overall Survival With Atezolizumab/Chemotherapy vs Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Carcinoma
In a final overall survival analysis of the phase III IMvigor130 trial reported in The Lancet Oncology, Enrique Grande, MD, and colleagues found no significant advantage in overall survival with atezolizumab plus chemotherapy vs chemotherapy alone in the first-line treatment of patients with...
MRD-Guided Ibrutinib/Venetoclax for Previously Untreated Patients With CLL
As reported in The New England Journal of Medicine by Talha Munir, MBBS, and colleagues, an analysis from the UK phase III FLAIR trial showed improved progression-free survival with measurable residual disease (MRD)-guided ibrutinib/venetoclax vs fludarabine/cyclophosphamide/rituximab (FCR) in...
Next-Generation Sequencing May Help Improve Access to Immunotherapy Among Patients With Cancer and Mismatch Repair Deficiency
Next-generation sequencing may help better identify patients with cancer and mismatch repair deficiency who may benefit from immunotherapy, according to a recent study published by Farhat et al in Cancer Cell. The new findings indicated that treating more patients with immunotherapy may require...
Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel may be a cost-effective second-line treatment option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Choe et al in Blood Advances. Background In cases...
2023 Members Appointed to the National Cancer Advisory Board
In addition to Dr. Richard J. Boxer, the following names have been newly appointed to serve a 5-year term on the National Cancer Institute’s National Cancer Advisory Board: Margaret Anne Anderson, Managing Director of Deloitte Consulting LLP, Arlington, Virginia Ysabel Duron, Founder and Executive ...
How Being a Member of the President’s National Cancer Advisory Board Is Contributing to High-Quality Oncology Care
This past year, President Joe Biden announced the appointment of six members to the National Cancer Advisory Board (NCAB; see related article). This board plays a crucial role in advising and assisting the director of the National Cancer Institute (NCI) in setting the activities of the national...
Expert Point of View: Noemí Reguart, MD, PhD
Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to...
Phase III Trial Shows Novel Four-Drug Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...
Can Immunotherapy Induce Sustained Disease Control Among Patients With Colorectal Cancer?
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and the third-leading cause of cancer-related deaths. According to the American Cancer Society, in 2023, it is estimated that about 52,550 individuals died from the...
Addition of Atezolizumab to Bevacizumab and Chemotherapy in Metastatic, Persistent, or Recurrent Cervical Cancer
As reported in The Lancet by Ana Oaknin, MD, and colleagues, the phase III BEATcc trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy improved progression-free and overall survival in women with metastatic, persistent, or recurrent cervical cancer. Study Details The...
Incidence of Second Primary Cancers in Adult Cancer Survivors
In a Danish population-based retrospective cohort study reported in The Lancet Oncology, Kjaer et al identified the cumulative incidence of second primary cancers among cancer survivors aged ≥ 40 years who were alive 1 year after diagnosis. Study Details The study involved data from 457,334...
IMvigor130: Atezolizumab vs Chemotherapy in Locally Advanced or Metastatic Urothelial Carcinoma
In the final overall survival analysis from the phase III IMvigor130 trial reported in The Lancet Oncology, Aristotelis Bamias, MD, and colleagues found no significant advantage in overall survival with atezolizumab monotherapy vs chemotherapy in untreated patients with locally advanced or...
Immune Checkpoint Inhibitor–Induced Myocarditis: Contemporary Retrospective Analysis
In a retrospective cohort study of 160 patients with cancer who were suspected of having immune checkpoint inhibitor (ICI)-induced myocarditis, published in JACC: CardioOncology, Osnat Itzhaki Ben Zadok, MD, MSc, and colleagues found that severe ICI-induced myocarditis seemed to be linked to...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
Novel Antibody-Drug Conjugate Under Study in Treatment of Gastric or Gastroesophageal Junction Cancers
A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may prove to be an effective treatment option for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: November 2023.1 (The ASCO Plenary Series is...
ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC
A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...
Expert Point of View: Christopher J. Sweeney, MBBS
Invited discussant of the PSMAfore trial, Christopher J. Sweeney, MBBS, Director of the South Australian Immunogenics Cancer Institute, University of Adelaide, Australia, congratulated the authors for a well-powered, controlled phase III trial. “The study showed clear documentation of...
Improving Cancer Control in a Changing World
On October 16 and 17, 2023, the Union for International Cancer Control (UICC) welcomed more than 350 attendees from over 75 countries to its World Cancer Leaders’ Summit in Long Beach, California, to discuss some of the most challenging issues facing patients with cancer worldwide. The theme of...
LuPSMA: Another Treatment Option for Metastatic Castration-Resistant Prostate Cancer
The use of lutetium-177–labeled PSMA-617 (LuPSMA) improved radiographic progression–free survival by 57% in men with metastatic castration-resistant prostate cancer who experienced disease progression on an androgen receptor (AR) pathway inhibitor compared with changing to a new AR pathway...
NIH Immunotherapy Pioneer Steven A. Rosenberg, MD, PhD, Awarded Nation’s Highest Honor for Technology and Innovation
Immunotherapy pioneer Steven A. Rosenberg, MD, PhD, has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation’s highest honor for technological achievement. Dr. Rosenberg is Chief of the Surgery Branch at the Center for Cancer Research at the National...
Neoadjuvant/Adjuvant Pembrolizumab in Resectable NSCLC
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
Overall Survival With LuPSMA vs Cabazitaxel in Previously Treated Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, overall survival results from the Australian phase II TheraP trial showed no difference with lutetium-177–labeled PSMA-617 (LuPSMA) vs cabazitaxel in patients with metastatic castration-resistant prostate cancer and...
EGFR-Mutated Advanced NSCLC: CNS Efficacy With Combination of Osimertinib and Chemotherapy
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...
Implementation of Updated WHO Screening Guidelines Could Reduce Cervical Cancer Mortality by Over 50% in Lower-Income Countries
Investigators have found that implementing the updated World Health Organization (WHO) screening guidelines may effectively reduce the cervical cancer mortality rate in patients residing in low- and middle-income countries, according to two recent studies published by Simms et al and Hall et al in...
New Findings Challenge Widely Accepted Beliefs About the Relative Efficacy of Opioids in Treating Cancer Pain
Investigators have uncovered concerningly large gaps in evidence regarding the true benefits of opioids for pain relief in patients with cancer, according to a novel study published by Shaheed et al in CA: A Cancer Journal for Clinicians. The new findings could challenge the commonly held view that ...
Imetelstat for RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes
As reported in The Lancet by Uwe Platzbecker, MD, and colleagues, the phase III IMerge trial has shown improved red blood cell transfusion independence with imetelstat, a competitive telomerase inhibitor, vs placebo in RBC transfusion-dependent patients with lower-risk myelodysplastic syndromes who ...
Community Program Cuts Treatment Delays in Half for Minority and Low-Income Patients
A program aimed at improving access to high-quality cancer care has significantly increased adherence to cancer treatment among minority and low-income communities, according to data presented at the 2023 ASCO Quality Care Symposium.1 The introduction of the ALCANCE-PLUS program in Monterey County, ...
The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning
A decade-long journey toward improving end-of-life care for patients with advanced cancer has demonstrated positive effects on survival, health-care use, and cost of care, according to data presented at the 2023 ASCO Quality Care Symposium.1 Post hoc analysis of an advance care planning...
Allogeneic Hematopoietic Stem Cell Transplantation for Dendritic Cell Neoplasm Subtype
Allogeneic hematopoietic stem cell transplantation can safely and effectively treat patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially during first remission, according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 4988). Results of the...
Overcoming BPDCN: Tagraxofusp Sets New Landmark in Patient Survival
A novel first-in-class therapy may help to redefine survival expectations for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 547). Results of a European named-patient program study showed...
Age, Race, and Sex Found to Impact Survival Rates in Patients With BPDCN
Age, race, and sex have significant implications for survival rates of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 5185). Findings from the largest U.S. population–based BPDCN study...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Expert Point of View: Susan Faye Dent, MD
In a joint ASCO/ICOS (International Cardio-Oncology Society) session presented at the 2023 Global Cardio-Oncology Summit, Dr. Anita Arnold and Dr. Krishnan Bhaskaran discussed the importance of understanding the impact of cancer therapy on the cardiovascular health of women. Medical oncologist...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Is Prediabetes Linked to Cardiovascular and Kidney Diseases in Adult Survivors of Childhood Cancer?
In a study reported in the Journal of Clinical Oncology, Dixon et al found that adult survivors of childhood cancers with prediabetes were at an increased risk of developing cardiovascular events and chronic kidney disease. The study involved data from 3,529 ≥ 5-year survivors of childhood cancer...
5-Year Outcomes of the IDEA Trial: Omission of Radiotherapy After Breast-Conserving Surgery for Low-Risk Patients
As reported in the Journal of Clinical Oncology by Reshma Jagsi, MD, DPhil, and colleagues, a 5-year analysis of the IDEA trial showed a very low rate of recurrence with the omission of radiotherapy after breast-conserving surgery in patients at low clinical and genomic risk for disease ...
Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
As reported in The New England Journal of Medicine by Kathleen N. Moore, MD, and colleagues, the phase III MIRASOL trial has shown improved progression-free and overall survival with mirvetuximab soravtansine-gynx vs chemotherapy in previously treated patients with folate receptor–alpha...
Psilocybin-Assisted Therapy May Reduce Depressive Symptoms in Patients With Cancer
Researchers have uncovered that psilocybin-assisted therapy may be safe and effective in patients with cancer and comorbid major depressive disorder, according to two novel studies published by Agrawal et al and Beaussant et al in Cancer. Background Psilocybin is a hallucinogenic chemical found in...
Lung Nodule Program May Help Detect Cancer in Patients Age-Ineligible for Lung Cancer Screening
Researchers have found that adopting a Lung Nodule Program may increase early lung cancer detection in patients who are not eligible for lung cancer screening under existing age-eligibility criteria, according to a recent study published by Liao et al in the Journal of Thoracic Oncology. ...
Childhood Cancer Survivors: Risk of Second Cancer and Heart Disease
In a French study of more than 7,000 childhood cancer survivors published by Charrier et al in JACC: CardioOncology, researchers reported that the occurrence of a second malignant neoplasm among these survivors seemed to be associated with an increased risk of cardiac disease occurrence and risk at ...
HPV ctDNA Detection After Chemoradiation in Patients With Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Han et al found that persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) after chemoradiation was associated with poorer outcomes in patients with cervical cancer. Patients at high risk of poorer outcomes could also be...
W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI
On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...
GLP-1 Receptor Agonists May Reduce Risk of Colorectal Cancer in Patients With High BMI and Diabetes
Glucagon-like peptide 1 (GLP-1) receptor agonists may be effective at reducing the risk of colorectal cancer in patients with a higher body mass index (BMI) and diabetes, according to a recent study published by Wang et al in JAMA Oncology. Background Obesity is a chronic health condition that...
Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781,...
